Quest Diagnostics to Partner with NCSS to Deliver Diagnostic Testing Services for Women in Ireland.
HEALTH AND BEAUTY CLOSE-UP-29 June 2008-Quest Diagnostics to Partner with NCSS to Deliver Diagnostic Testing Services for Women in Ireland(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Women in Ireland will soon be able to take advantage of diagnostic testing services provided by Quest Diagnostics, a provider of cervical-cancer screening...

Quest Diagnostics to Develop Blood Test to Aid in the Detection of Colorectal Cancer.
HEALTH AND BEAUTY CLOSE-UP-19 February 2008-Quest Diagnostics to Develop Blood Test to Aid in the Detection of Colorectal Cancer(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Quest Diagnostics, a provider of diagnostic testing, information and services, announced that it has licensed rights to uses of the Septin 9 DNA methylation...

Quest Diagnostics Announces Licensing Agreement for Genetic Testing Technology to Screen for Most Common Inherited Mental Impairment, Fragile X Syndrome.
New Technology Will Allow for Widespread Population-Based Carrier Screenings LYNDHURST, N.J., Jan. 19 /PRNewswire-FirstCall/ -- In a move that promises to advance physicians' ability to widely screen for Fragile X Syndrome (FXS), the most common form of inherited mental retardation,(1) Quest Diagnostics Incorporated today announced the signing...

Is the human papillomavirus test in combination with the papanicolaou test useful for management of patients with diagnoses of atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions?
Although introduction of the Papanicolaou (Pap) test has reduced the incidence of cervical carcinoma, it remains the second or third most common malignancy in women worldwide. (1) Since the introduction of the Pap test, 4 reporting systems have been used. (2) The Bethesda System is the most recently adopted...

Regulating biomedicine in Belgium and France: neighboring countries, diverging policies.
1. Introduction The invention of the technique of in-vitro fertilization (IVF) in the late 1970s and its routinization in the mid-1980s created the basis for new medical techniques, such as intracytoplasmic sperm injection (ICSI), pre-implantation diagnostics, genetic screening and engineering, as well as new fields for biomedical...

CHEO Leverages Luminex Technology.
HEALTH AND BEAUTY CLOSE-UP-30 June 2008-CHEO Leverages Luminex Technology(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com The Ontario Newborn Screening Program, located at the Children's Hospital of Eastern Ontario (CHEO), recently announced that it has accomplished the Ministry of Health and Long-Term Care's mandate to screen all babies born in...

Video: Quest Diagnostics Acquires HemoCue for Approximately $420 Million, Entering Market for Near Patient Testing.
LYNDHURST, N.J., Feb. 1 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated , the leading U.S. provider of diagnostic testing, information and services, announced today that it has acquired HemoCue, a Swedish company specializing in near patient testing, also known as point-of- care testing, from the private equity firm EQT II B.V....

Seroprevalence of human immunodeficiency virus and syphilis infections among patients attending the STD, Gyn. and Obs., ANC Clinics of Northern India: observations from seven rounds of sentinel surveillance (1998-2004).
Abstract: The data of HIV sentinel surveillance, i.e., National Annual Sentinel Surveillance (NASS) carried out under the aegis of National AIDS Control Organisation (NACO) of seven rounds revealed that the prevalence of HIV infection is less among the attendees of STD, Obs.& Gyn., Antenatal (ANC) clinics whereas that of...

CytoLogix Awarded US Patent for Its Next Generation Cellular Diagnostics Technology.
Cellular Diagnostics Fueled by Advances in Molecular Biology and Genomics, Major Application is Accurate Diagnosis and Prognosis of Cancer CAMBRIDGE, Mass., Jan. 30 /PRNewswire/ -- CytoLogix Corporation today announced that it was awarded a new U.S. Patent: #6,180,061, "Moving Platform Slide Stainer With...

Sequenom and Lenetix Enter Agreement to Develop and Commercialize Rhesus D Prenatal Diagnostic.
Sequenom's First Non-Invasive Prenatal Diagnostic Test On Track to Launch in First Half of 2007 SAN DIEGO and MINEOLA, N.Y., Jan. 29 /PRNewswire-FirstCall/ -- Sequenom, Inc. and Lenetix Medical Screening Laboratory, Inc., a provider of rapid genetic screening and diagnostic testing for clinicians worldwide, today announced that...